[{"innerBlocks":[],"name":"core\/freeform","postId":2968,"blockType":{"name":"core\/freeform","keywords":[],"attributes":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"providesContext":[],"usesContext":[],"selectors":[],"supports":{"className":false,"customClassName":false,"reusable":false},"styles":[],"variations":[],"apiVersion":3,"title":"Classic","description":"Use the classic WordPress editor.","category":"text"},"originalContent":"A new service available to Intermountain Healthcare providers will enable them to implement personalized medicine when prescribing antidepressants and to gain a better understanding of how genes affect their patients\u2019 responses to the drugs.

Available through Intermountain Precision Genomics Core Laboratory in St. George, Utah, the RxMatch Antidepressant Panel was launched earlier this month and considers how the liver and brain process such medications by enabling physicians to leverage genomic information to find the right antidepressant faster than using current trial-and-error methods.

Also See:<\/b> Mayo Clinic uses EHRs, genetics to tailor patients\u2019 antidepressants<\/a>

As part of an initial pilot program in southwest Utah, the service will be offered to Intermountain Healthcare physicians who will collect a DNA sample from patients using a cheek swab in their offices, which will then be sent to the Intermountain Precision Genomics Core Laboratory and analyzed.

\u201cThe objective of the RxMatch<\/a> project is to provide the most comprehensive and evidence-based information to the physician, thus decreasing the amount of time and money spent to achieve the correct medication at the lowest possible cost to the patient,\u201d said David Loughmiller, laboratory manager for Intermountain Precision Genomics.

The service is powered by CNSDose, a vendor selected by Intermountain to deliver clinical decision support based on its expertise in the area of liver and blood-brain-barrier metabolism of antidepressant medications.

According to Mark Heinemeyer, CEO of CNSDose, his company\u2019s solution is the most rigorously tested tool on the market. He points to a recently conducted randomized controlled study in which CNSDose demonstrated a 250 percent improvement in remission rates for patients suffering from depression over a three-month period, as well as reduced associated side effects.

\u201cWe\u2019re thrilled to be working with Intermountain Healthcare to get CNSDose into the hands of more patients suffering from the debilitating effects of depression,\u201d said Heinemeyer.
","saveContent":"A new service available to Intermountain Healthcare providers will enable them to implement personalized medicine when prescribing antidepressants and to gain a better understanding of how genes affect their patients\u2019 responses to the drugs.

Available through Intermountain Precision Genomics Core Laboratory in St. George, Utah, the RxMatch Antidepressant Panel was launched earlier this month and considers how the liver and brain process such medications by enabling physicians to leverage genomic information to find the right antidepressant faster than using current trial-and-error methods.

Also See:<\/b> Mayo Clinic uses EHRs, genetics to tailor patients\u2019 antidepressants<\/a>

As part of an initial pilot program in southwest Utah, the service will be offered to Intermountain Healthcare physicians who will collect a DNA sample from patients using a cheek swab in their offices, which will then be sent to the Intermountain Precision Genomics Core Laboratory and analyzed.

\u201cThe objective of the RxMatch<\/a> project is to provide the most comprehensive and evidence-based information to the physician, thus decreasing the amount of time and money spent to achieve the correct medication at the lowest possible cost to the patient,\u201d said David Loughmiller, laboratory manager for Intermountain Precision Genomics.

The service is powered by CNSDose, a vendor selected by Intermountain to deliver clinical decision support based on its expertise in the area of liver and blood-brain-barrier metabolism of antidepressant medications.

According to Mark Heinemeyer, CEO of CNSDose, his company\u2019s solution is the most rigorously tested tool on the market. He points to a recently conducted randomized controlled study in which CNSDose demonstrated a 250 percent improvement in remission rates for patients suffering from depression over a three-month period, as well as reduced associated side effects.

\u201cWe\u2019re thrilled to be working with Intermountain Healthcare to get CNSDose into the hands of more patients suffering from the debilitating effects of depression,\u201d said Heinemeyer.
","order":0,"get_parent":{},"attributes":[],"attributesType":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"dynamicContent":""}]

New Intermountain service aims to aid antidepressant efficacy

More for you